Cara Therapeutic Stock Price, News & Analysis

Welcome to our dedicated page for Cara Therapeutic news (Ticker: CARA), a resource for investors and traders seeking the latest updates and insights on Cara Therapeutic stock.

Cara Therapeutics (NASDAQ: CARA) was a clinical-stage biotechnology company that specialized in developing peripherally-acting kappa opioid receptor agonists for pruritus and pain. The company has since merged with Tvardi Therapeutics and now operates under the ticker symbol TVRD. This page serves as a historical news archive for Cara Therapeutics.

Throughout its history as an independent company, Cara Therapeutics generated news related to its clinical development programs, regulatory submissions, and commercialization efforts for difelikefalin, its lead drug candidate for uremic pruritus in hemodialysis patients. The company achieved regulatory approvals in the United States, European Union, and other markets, marking significant milestones in treating this underserved patient population.

This archive documents Cara's journey as a biotechnology company, including clinical trial results, FDA interactions, partnership announcements, and the eventual corporate transformation through its merger with Tvardi Therapeutics. For investors and researchers studying the development of kappa opioid receptor agonists or the treatment of chronic kidney disease-associated pruritus, these historical news items provide valuable context.

News coverage in this archive includes regulatory milestones for difelikefalin, investor communications, corporate announcements, and the events leading to the Tvardi merger. For current news about the combined company, please refer to the TVRD ticker page.